NC Life Sciences Organization’s Post

Check out @weworkforhealth’s latest blog to learn more about new IRA analysis from @IQVIA_global and understand IRA shortcomings from patient and innovator perspectives. Read more here: https://lnkd.in/eNbB6Dq2

Join us for Building High-Performing Teams Through Inclusive Leadership with Amgen, mdgroup and The Diversity Movement on Wednesday, July 24, from 4 to 6 p.m. at the NC Biotech Center. Come ready to network with industry leaders and to hear a panel discussion exploring proven inclusive leadership development strategies. Learn more and register at https://lnkd.in/gSD3N-hj

Novo Nordisk today announced plans to invest $4.1 billion dollars to build a second fill and finishing manufacturing facility in Clayton and grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases. Marking one of the largest manufacturing investments in Novo Nordisk’s history, the expansion will add 1.4 million square feet of production space for aseptic manufacturing and finished production processes, doubling the combined square footage of all three of the company’s existing facilities in North Carolina. It will also add 1,000 new jobs, besides the nearly 2,500 Novo Nordisk employees already working in the region, a central hub for innovation and biotechnology in the United States. Using state-of-the-art technology, roof-top solar panels and innovative water strategies, the facility is designed in an efficient and environmentally sustainable way to deliver the highest-quality products to patients around the world. The goal is to obtain LEED Gold certification, recognised as a standard of excellence in constructing healthy, efficient, carbon and cost-saving green buildings. https://lnkd.in/g-SG4EHy

A big thank you to Sen. Thom Tillis and Sen. Ted Budd for taking the time today to talk with NCLifeSci members about the R&D tax credit, the #smallmoleculepenalty in the #InflationReductionAct and IP protection and for answering members' questions.

“Fortunately, federal lawmakers have recognized the negative impact the pill penalty could have on new drug development. The bipartisan EPIC Act would equalize the period of price-control exemptions for small-molecule drugs and biologics at 13 years. This fix would once again put life sciences research back on a path to following the science, not a distorted incentive structure. That’s the right way forward for North Carolina innovators.” – Laura Gunter, NCLifeSci President In a recent opinion for The Carolina Times, NCLifeSci President Laura Gunter applauds Representatives Davis (NC-1), Murphy (NC-3), and Guthrie (KY-2) for introducing the Ensuring Pathways to Innovate Cures (EPIC) Act. Congress must pass the #EPICAct and ensure continued investment into new and innovative drug development here in North Carolina. Learn more about how the EPIC Act will protect innovation and support North Carolina’s robust life sciences industry in Gunter’s new op-ed: bit.ly/3VuW4KR